

22 **ABSTRACT**

23 **Introduction:** Matrix metalloproteinases (MMP) have been identified as biomarkers for
24 several diseases, including cancer. MMP-26 is constitutively expressed in some cancer
25 cells of epithelial origin. Despite this, there is a lack of studies regarding the expression
26 of MMP-26 on prostatic carcinoma. **Aim:** Here, we investigate the expression of the
27 MMP-26 peptide in benign and malign prostatic tissues. **Patients and Methods:** For this,
28 150 specimens, including atrophy (N = 25), prostatic intraepithelial neoplasia (PIN) (N =
29 25), benign prostatic hyperplasia (BPH) (N = 50), and prostatic adenocarcinoma (PA) (N
30 = 50), were immunohistochemically (IHC) examined for the expression of MMP-26.
31 **Results:** MMP-26 expression was positive in 70 (46.7%) out of the 150 samples, being
32 more prevalent in the PA group (46/50 cases,92%), followed by PIN (22/25 cases, 88%).
33 The BPH group showed only 2/50 (4%) positive cases, and the atrophy group showed no
34 reactivity. ROC curve analysis showed that MMP-26 immunoexpression had a higher
35 area under the curve between PA vs atrophy+PIN+BPH (AUC=0.94; 95% CI 0.9-0.98),
36 PA+PIN vs atrophy+BPH (AUC=0.97; 95% CI 0.94-0.99) and PA vs atrophy+BPH
37 (AUC=0.97; 95% CI 0.95-1.00) groups. In addition, the expression and intensity of the
38 MMP-26 reaction showed a significant association with total PSA values ($P=0.001$).
39 **Conclusions:** Our results showed that MMP-26 immunoexpression was useful to
40 differentiate a group of benign and malignant samples in prostate tumors. This
41 characteristic could assist in the predictive assessment and, consequently, in the
42 development of new strategies for the diagnosis, prognosis, and treatment of prostate
43 cancer.

44

45 **KEYWORDS:** Matrix Metalloproteinase-26 (MMP-26), Immunohistochemistry (IHC),
46 Prostate-Specific Antigen (PSA), Prostate cancer.

47 INTRODUCTION

48 Prostate cancer (PC) is one of the most prevalent cancers worldwide, ranking second
49 among malignant neoplasms that affect men ¹. PC screening tools include serum prostate-
50 specific antigen (PSA) measurement, rectal examination, and biopsy. Despite its name,
51 PSA has low specificity presenting with high levels in benign conditions such as
52 prostatitis and hyperplasia, which results in unnecessary treatment and elevated rates of
53 negative biopsy results ². Therefore, research of new biomarkers for early, differential
54 diagnosis and with potential for PC prognostic value has been undertaken.

55 Matrix metalloproteinase (MMPs) are endopeptidases that promote degradation and
56 remodeling of the extracellular matrix and play an essential role in various physiological
57 and pathological processes ³. Its exacerbated expression is associated with invasion,
58 angiogenesis, metastasis, and poor prognosis of several types of cancer, such as thyroid
59 ⁴, breast ⁵, and prostate ⁶. MMP-26 is the smallest molecule in the MMP family that was
60 recently discovered. Its constitutive expression was described in the endometrium and
61 placenta, as well as in cancer cells of epithelial origin ⁷. Its primary substrates include
62 fibronectin, fibrinogen, vitronectin, laminin, and type IV collagen. MMP-26 also can
63 activate pro-MMP-9, known to promote invasion and angiogenesis in several human
64 tumors ⁸.

65 High expression of MMP-26 has been demonstrated in breast, lung, liver, endometrial,
66 ovarian, and esophageal cancer cell lines ⁹⁻¹⁴. Nevertheless, research on its role in PC is
67 still scarce. Recently, the prognostic value of MMP-26 has been evaluated in colorectal
68 cancer, where significant expression was associated with invasion, metastasis, and lower
69 overall patient survival ¹⁵. MMP-26 was also significantly higher in both serum and tissue
70 of patients with PC ¹⁶. Despite this, there are fewer studies devoted to the MMP-26 and
71 PC. Hence, we investigate the expression of the MMP-26 in benign and malign prostatic

72 tissues and its relation with PSA as putative biomarkers for differentiating PC patients
73 from atrophy, prostatic intraepithelial neoplasia (PIN), and benign prostatic hyperplasia
74 (BPH) patients.

75

76 **PATIENTS AND METHODS**

77 ***Patients***

78 One hundred and fifty histological samples were obtained from patients presenting with
79 prostatic lesions and treated at the *Clinical Hospital of Federal University of Pernambuco*
80 (HC/UFPE). The samples were divided into 4 groups, based on its histopathological
81 classification: prostatic atrophy (N = 25), prostatic intraepithelial neoplasia (PIN) (N =
82 25), benign prostatic hyperplasia (BHP) (N = 50) and prostatic adenocarcinoma (PA) (N
83 = 50). Tumor samples in paraffin blocks were obtained from the Pathology department
84 of the hospital along with their respective clinical reports. Clinical data such as PSA
85 dosage, patient age, and ethnicity were obtained from medical records. The UFPE
86 research ethics board reviewed the protocol and approved the study (approval number
87 CAAE 79701517100005208).

88

89 ***Immunohistochemistry analysis***

90 Blocks containing representative parts of the tumor were subjected to microtomy
91 generating 5 μ slices, followed by processing and reactivity. Each slide was deparaffinized
92 in xylol, bathed in decreasing solutions of ethyl alcohol (100%, 100%, and 70%), and
93 deionized water for 5 minutes. After antigenic recovery with citrate buffer (10 mM, pH
94 6.0) and blocking of endogenous peroxidase and other proteins using the Envision Flex

95 kit (Dako Denmark A / S), samples were incubated with anti-MMP-26 (FNab 05242, Fine
96 Test, 1: 500) in a humid chamber, overnight at 4°C. The material was subsequently
97 immersed in phosphate-buffered saline (PBS, 100 mM, pH 7.2) and incubated with the
98 HRP polymer (Horseradish peroxidase). After PBS wash, the samples were incubated
99 with the Diaminobenzidine developer (DAB), counterstained with hematoxylin,
100 immersed in running water, and increasing alcoholic solution (70%, 100%, and 100%)
101 for 5 minutes each. Finally, the slides were immersed in xylol and assembled with
102 coverslips interfaced with synthetic resin. Negative controls were performed using the
103 same protocol in the absence of the primary antibody. Endometrial adenocarcinoma
104 samples were used for positive controls.

105

106 ***Image Collection and Analysis***

107 Labeled cells were observed using a Zeiss AxioCam microscope and a Zen Blue image
108 capture system (edition 2011). Manual quantification was used where the parenchymal
109 epithelial cells were evaluated. The reaction was considered as negative when less than
110 four epithelial cells were marked per field, and positive when more than four marked cells
111 were observed per field. The intensity of the reaction was evaluated semiquantitatively
112 according to the reaction in the nucleus or cytoplasm of the cells: weak (04 to 09 nuclei
113 or reactive cytoplasms), moderate (10 to 15 nuclei or reactive cytoplasms), and intense
114 (above 15 nuclei or reactive cytoplasms).

115

116 ***Statistical Analysis***

117 Categorical variables were analyzed by the Chi-Square test, the Fisher's Exact Test, and
118 the Likelihood Ratio Test, according to data distribution. Numerical variables were

119 analyzed with the Kruskal-Wallis test. Positive and negative IHC were compared through
120 the Mann-Whitney test. Area under a receiver operating characteristic (ROC) was
121 calculated to estimated sensitivity and specificity for tests. Statistical significance was judged
122 at the 0.05 level. IMB-SPSS version 23 was used to perform the analyses.

123

124 **RESULTS**

125 *Characteristics of the study population*

126 The age of the study population ranged from 41 to 88 years, with a mean of 66.8 years of
127 age. Patients aged 60 to 69 years represented the most prevalent age group (45.3%),
128 followed by patients aged 70 or over (36.7%), with the remaining 18% having between
129 41 to 59 years of age ($P=0.447$). Ethnicity was different between groups, being patients
130 identified as mixed-race comprised the most prevalent ethnic group (44%), followed by
131 19.3% of afro-Brazilians and Caucasian (10%) ($P=0.010$). Ethnic information was absent
132 for 26.7% of the sample. Regarding risk habits for prostatic diseases, 29.3% of the
133 participants reported alcohol consumption ($P=0.286$) and 32.7% were smokers
134 ($P=0.649$).

135

136 *Analysis of patients' PSA levels*

137 Measurements of the patient's PSA levels were obtained from medical records and divided
138 according to serum levels: up to 4 ng/ml (24.7%), 4 to 10 ng/ml (48%), greater than 10
139 ng/ml (18%). PSA levels were absent for 14 patients. PA samples presented with the
140 highest percentages of PSA levels (26.7%), followed by BHP (19.3%), and atrophy
141 (17.3%) (Table 2). Table 3 summarizes PSA levels in the study population. A significant

142 difference was observed between groups ($P = 0.002$). The percentage of PSA value in the
143 range of 4 to 10 was higher in the group with atrophy (69.6%) and lower in the BHP group
144 (40.0%), while the percentage with PSA up to 4 was higher in the BHP group (47.5%),
145 lower in the PA group (12.5%) and varied from 24.0% to 26.1% in the remaining two
146 groups. The mean and median of total PSA were correspondingly higher in the PA group
147 when compared to the other groups, with the lower occurring in the atrophy group. We
148 observed a significant difference between the PA group and the other remaining groups.

149

150 ***Analysis of MMP-26 expression by immunohistochemistry***

151 MMP-26 expression measured by IHC was positive in 70 (46.7%) out of the 150 samples,
152 being more prevalent in the PA group (46/50 cases, 92%), followed by PIN (22/25 cases,
153 88%). The BHP group showed only 2/50 (4%) positive cases, and the atrophy group
154 showed no reactivity (Figure 1). Weak immunostaining was observed in 34 (48.6%) of the
155 70 positive samples, 22 in the PIN group, 2 in the BHP, and 10 in the PC group. Moderate
156 and intense reactivity occurred, in 31 (44.2%) and 5 (7.14%) of the positive cases, all of
157 them in the PA group. The marking pattern was nuclear and cytoplasmic (Table 4). ROC
158 curve analysis showed that areas under the ROC curves were larger in PA vs
159 atrophy+PIN+BHP (AUC=0.94; 95% CI 0.9-0.98), PA+PIN vs atrophy+BHP (AUC=0.97;
160 95% CI 0.94-0.99) and PA vs atrophy+BHP (AUC=0.97; 95% CI 0.95-1.00) groups (Table
161 6; Figures 2, 3 and 4).

162

163 ***Analysis of the relationship between IHC and PSA***

164 The expression of MMP-26 by IHC showed a significant association with total PSA values.
165 The greatest difference occurred in the PSA group with up to 4 ng/ml, where most cases

166 showed negative IHC (38.6%), followed by the PSA group greater than 10 ng/ml, where
167 values were higher among those who had positive IHC (28, 8%). An association was also
168 found between the intensity of the reaction and PSA values. There was a variation of 15%
169 to 17% between the weak and moderate intensities in the PSA group with up to 4 ng/ml
170 and 40% in the intense reaction for the PSA group greater than 10 ng/ml (Table 5).

171

172 **DISCUSSION**

173 Since the 1980s, with the introduction of the PSA test in the medical routine, there
174 has been a significant increase in the diagnostic of PC cases and a 20% reduction in the
175 PC mortality rate. Serum PSA is measured for early detection, staging, and monitoring of
176 the disease. However, it might have low specificity when the values range between 3 and
177 10 ng/ml, and also showing an increase in benign conditions such as BHP and prostatitis
178 ^{2,16}. The search for new biomarkers, which combined with PSA can provide greater
179 precision in the diagnosis, has led to several studies on the expression of MMP, both in
180 serum and in tissue samples of PC.

181 Kanoh et al. (2002) and Zhang et al. (2004) observed, high serum levels of MMP-2 and
182 MMP-9 in patients with PC and BHP, with increasing expression as the disease
183 progressed ^{17,18}. In addition to MMP-2 and -9, Morgia et al. (2005) found that MMP-13
184 levels were significantly higher levels in patients with PC ¹⁹. MMP-7 was analyzed by
185 Szarvas et al. (2011), and its levels were also strongly elevated, especially in patients with
186 metastatic PC ²⁰. In 2005, Riddick et al. evaluated the expression of MMP-10, -15, -24, -
187 25, and -26, of which MMP-26 was the one showing the highest degree of expression in
188 malignant prostate tissues, strongly correlating with the Gleason score ²¹.

189 Recently, Cheng et al. (2017) observed a marked increase and strong
190 immunoreactivity of MMP-26 in the serum, in PC samples compared to the BHP and
191 control groups¹⁶. Also, Zhao et al. (2003) noted that MMP-26 was able to activate MMP-
192 9 in PC cells, an essential mechanism in the invasion and metastasis process²². An assay
193 with specific inhibitors for MMP-26 generated a reduction in MMP-9 and a significant
194 decrease in the invasive potential of these cells. These findings support the hypothesis
195 that the activation of MMP-9 by MMP-26 may promote an increase in cell invasiveness
196 and, consequently, a worse clinical outcome.

197 Our results also demonstrated a higher expression of MMP-26 in cases of PA
198 (63%), in addition to a positive association between the IHC expression of MMP-26 with
199 PSA values, which suggests that this enzyme could be used as an adjunct to the
200 measurement of this marker for the differential diagnosis between PA and BHP, as well
201 as for estimating the prognosis of cancer given that it has also shown weak reactivity in
202 NIP samples. The rupture of continuity between the cell layer and the basement
203 membrane is essential for the progression from intraepithelial neoplasia to prostate
204 carcinoma. Lee et al. (2006) found a higher expression of MMP-26 in cases of PIP
205 compared to PC and that its levels declined in the progression to invasive cancer²³. His
206 findings suggest that MMP-26 might play an important during tissue transformation
207 between these lesions, serving as an early marker of prostate cancer.

208 The prognosis of PC is also associated with age, with older age being the best-
209 established risk factor. Studies indicate that both incidence and mortality increase after
210 age 50, with three-quarters of new cases around age 65^{2,16}. In this context, we observed
211 that 56% of the patients with PA in our study were between 60 and 69 years old.
212 Moreover, our findings showed total negativity for MMP-26 in the group of atrophic
213 cases, which might be useful for therapeutic definition as a predictive marker in such

214 patients who also have high PSA. Furthermore, MMP-26 can be measured in serum, as
215 described by Cheng et al. (2017) in their study ¹⁶. Thus, it would be possible to
216 concomitantly evaluate PSA and MMP-26 in the same blood sample and estimate the
217 outcome of patients at risk in a given age group.

218 Ethnicity can also be a risk factor, blacks are more susceptible, according to a
219 study by Noone et al. (2017), which contradicts our results: 44% of the samples were
220 obtained from mixed races and 19% from blacks (with 10% presenting CP) ²⁴. It is known
221 that smoking promotes an increase in mortality among patients with CP ²⁵. However, this
222 association was also not found and can be explained by the case selection being based on
223 histopathological alteration and not spontaneous demand.

224 Unlike most MMPs, MMP-26 is expressed in the intracellular region ⁸. The
225 cytoplasmic immunoreactivity of MMP-26 was evidenced by Guo et al. (2018) in glioma
226 cells and by Hu et al. (2014) in colorectal carcinoma ^{15,26}. We observed both a cytoplasmic
227 and nuclear pattern in malignant PC. This differentiated location enables new roles for
228 this enzyme. Although the expression of MMP-26 is elevated in several types of cancer
229 such as liver, lung, and breast cancer ⁹⁻¹¹, some studies have also revealed protective
230 functions in the regulation of inflammation and apoptosis ^{8,27,28}.

231 Khamis et al. (2013) suggested an anti-inflammatory role for MMP-26 ⁸. Cells
232 transfected with MMP-26 cDNA showed low regulation of inflammatory genes, whereas
233 cells with the silenced gene had reduced IL-10 receptor (IL10R), suggesting that MMP-
234 26 deficiency may promote inflammation by inhibiting the IL10R pathway.
235 Subsequently, Khamis et al. (2016) provided evidence for a protective role in the prostate
236 ²⁷. It was observed that prostate tumor cells expressing MMP-26 underwent apoptosis via
237 Bax and that MMP-26 overload would have a pro-apoptotic function, reducing the degree
238 of invasion and disease progression. It was also observed by Savinov et al. (2006) that

239 the elevation of MMP-26 resulted in a favorable prognosis and increased survival of
240 patients with breast carcinoma *in situ* ²⁸.

241 Given the versatile profile of MMP-26, there is still much to be investigated.
242 However, several studies have demonstrated its potential as a tumor marker, especially
243 for prostatic carcinoma. In this study, we showed that the MMP-26 IHC can be potentially
244 useful to differentiate benign and malignant cases of the prostate, and may assist in the
245 development of new strategies for the diagnosis, prognosis, and treatment of prostate
246 cancer.

247

248 **ACKNOWLEDGMENTS**

249 This work was supported by CAPES (Coordination for the Improvement of Higher
250 Education Personnel), LIKA (Keizo Asami Immunopathology Laboratory), and LPCM
251 (Cytological and Molecular Research Laboratory).

252

253 **AUTHORS 'CONTRIBUTION**

254 All authors contributed to the conception and design of the study. The collection
255 and processing of the material, as well as the immunohistochemical analyzes, were
256 performed by Romildo Luciano da Silva, Francisco Luís Almeida Paes, and Sandra Maria
257 Souza da Silva. The analysis of the data and results obtained was carried out by Jacinto
258 Costa da Silva Neto. Ingrid Tavares de Lima did the drafting of the manuscript. The
259 revision and editing of the manuscript were carried out by Ana Pavla Almeida Diniz
260 Gurgel and Jacinto Costa da Silva Neto. The financing was acquired by Jacinto Costa da

261 Silva Neto. The research was supervised by Jacinto Costa da Silva Neto. All authors read
262 and approved the final manuscript.

263

264 **APPROVAL OF ETHICS**

265 The Research Ethics Committee approved this study of the Health Sciences Center of the
266 Federal University of Pernambuco (CEP / CCS / UFPE) under CAAE:
267 79701517100005208

268

269 **CONFLICT OF INTERESTS**

270 Non-existent

271

272 **REFERENCES**

- 273 1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources,
274 methods and major patterns in GLOBOCAN 2012. *Int J Cancer*. 2015;136(5):E359-386.
275 doi:10.1002/ijc.29210
- 276 2. El-Chaer WK, Moraes CF, Nóbrega OT. Diagnosis and Prognosis of Prostate Cancer from
277 Circulating Matrix Metalloproteinases and Inhibitors. *J Aging Res*. 2018;2018.
278 doi:10.1155/2018/7681039
- 279 3. Oktora M, Oktora MZ, Putriyuni A. Expression of Matrix Metalloproteinases in Thyroid Follicular
280 Neoplasm Fna. *ijmsci*. 2020;7(09):4965-4967. doi:10.18535/ijmsci/v7i09.05
- 281 4. Meng X-Y, Zhang Q, Li Q, Lin S, Li J. Immunohistochemical levels of cyclo-oxygenase-2, matrix
282 metalloproteinase-9 and vascular endothelial growth factor in papillary thyroid carcinoma and their
283 clinicopathological correlations. *J Int Med Res*. 2014;42(3):619-627.
284 doi:10.1177/0300060513505485
- 285 5. Cid S, Eiro N, Fernández B, et al. Prognostic Influence of Tumor Stroma on Breast Cancer
286 Subtypes. *Clin Breast Cancer*. 2018;18(1):e123-e133. doi:10.1016/j.clbc.2017.08.008
- 287 6. Pouyanfar N, Monabbati A, Sharifi AA, Dianatpour M. Expression Levels of MMP9 and PIWIL2
288 in Prostate Cancer: a Case-Control Study. *Clin Lab*. 2016;62(4):651-657.
289 doi:10.7754/clin.lab.2015.150817

- 290 7. Park HI, Ni J, Gerkema FE, Liu D, Belozarov VE, Sang QX. Identification and characterization of
291 human endometase (Matrix metalloproteinase-26) from endometrial tumor. *J Biol Chem.*
292 2000;275(27):20540-20544. doi:10.1074/jbc.M002349200
- 293 8. Khamis ZI, Zorio DAR, Chung LWK, Sang Q-XA. The Anti-inflammatory Role of
294 Endometase/Matrilysin-2 in Human Prostate Cancer Cells. *J Cancer.* 2013;4(4):296-303.
295 doi:10.7150/jca.5788
- 296 9. Lee S, Terry D, Hurst DR, Welch DR, Sang Q-XA. Protein Signatures in Human MDA-MB-231
297 Breast Cancer Cells Indicating a More Invasive Phenotype Following Knockdown of Human
298 Endometase/Matrilysin-2 by siRNA. *J Cancer.* 2011;2:165-176. doi:10.7150/jca.2.165
- 299 10. Zhao D, Lu Y, Yang C, Zhou X, Xu Z. Activation of FGF receptor signaling promotes invasion of
300 non-small-cell lung cancer. *Tumour Biol.* 2015;36(5):3637-3642. doi:10.1007/s13277-014-3001-y
- 301 11. Yu C, Wang Z, Xu X, Xiang W, Huang X. Circulating Hepatocellular Carcinoma Cells are
302 Characterized by CXCR4 and MMP26. *Cell Physiol Biochem.* 2015;36(6):2393-2402.
303 doi:10.1159/000430201
- 304 12. Nishi H, Kuroda M, Isaka K. Estrogen and estrogen receptor induce matrix metalloproteinase-26
305 expression in endometrial carcinoma cells. *Oncology Reports.* 2013;30(2):751-756.
306 doi:10.3892/or.2013.2527
- 307 13. Ripley D, Tunuguntla R, Susi L, Chegini N. Expression of matrix metalloproteinase-26 and tissue
308 inhibitors of metalloproteinase-3 and -4 in normal ovary and ovarian carcinoma. *Int J Gynecol*
309 *Cancer.* 2006;16(5):1794-1800. doi:10.1111/j.1525-1438.2006.00714.x
- 310 14. Yamamoto H, Vinitketkumnien A, Adachi Y, et al. Association of matrilysin-2 (MMP-26)
311 expression with tumor progression and activation of MMP-9 in esophageal squamous cell
312 carcinoma. *Carcinogenesis.* 2004;25(12):2353-2360. doi:10.1093/carcin/bgh270
- 313 15. Hu Q, Yan C, Xu C, et al. Matrilysin-2 expression in colorectal cancer is associated with overall
314 survival of patients. *Tumour Biol.* 2014;35(4):3569-3574. doi:10.1007/s13277-013-1471-y
- 315 16. Cheng T, Li F, Wei R, et al. MMP26: A potential biomarker for prostate cancer. *CURR MED SCI.*
316 2017;37(6):891-894. doi:10.1007/s11596-017-1823-8
- 317 17. Kanoh Y, Akahoshi T, Ohara T, et al. Expression of matrix metalloproteinase-2 and prostate-
318 specific antigen in localized and metastatic prostate cancer. *Anticancer Res.* 2002;22(3):1813-1817.
- 319 18. Zhang L, Shi J, Feng J, Klocker H, Lee C, Zhang J. Type IV collagenase (matrix metalloproteinase-
320 2 and -9) in prostate cancer. *Prostate Cancer and Prostatic Diseases.* 2004;7(4):327-332.
321 doi:10.1038/sj.pcan.4500750
- 322 19. Morgia G, Falsaperla M, Malaponte G, et al. Matrix metalloproteinases as diagnostic (MMP-13)
323 and prognostic (MMP-2, MMP-9) markers of prostate cancer. *Urol Res.* 2005;33(1):44-50.
324 doi:10.1007/s00240-004-0440-8
- 325 20. Szarvas T, Becker M, Dorp F vom, et al. Elevated serum matrix metalloproteinase 7 levels predict
326 poor prognosis after radical prostatectomy. *International Journal of Cancer.* 2011;128(6):1486-
327 1492. doi:https://doi.org/10.1002/ijc.25454
- 328 21. Riddick ACP, Shukla CJ, Pennington CJ, et al. Identification of degradome components associated
329 with prostate cancer progression by expression analysis of human prostatic tissues. *British Journal*
330 *of Cancer.* 2005;92(12):2171-2180. doi:10.1038/sj.bjc.6602630
- 331 22. Zhao Y-G, Xiao A-Z, Newcomer RG, et al. Activation of pro-gelatinase B by
332 endometase/matrilysin-2 promotes invasion of human prostate cancer cells. *J Biol Chem.*
333 2003;278(17):15056-15064. doi:10.1074/jbc.M210975200

- 334 23. Lee S, Desai KK, Iczkowski KA, et al. Coordinated peak expression of MMP-26 and TIMP-4 in
335 preinvasive human prostate tumor. *Cell Research*. 2006;16(9):750-758. doi:10.1038/sj.cr.7310089
- 336 24. Cancer Statistics Review, 1975-2015 - Previous Version - SEER Cancer Statistics Review. SEER.
337 Accessed November 9, 2020. https://seer.cancer.gov/archive/csr/1975_2015/index.html
- 338 25. Wilson KM, Markt SC, Fang F, et al. Snus use, smoking and survival among prostate cancer
339 patients. *Int J Cancer*. 2016;139(12):2753-2759. doi:10.1002/ijc.30411
- 340 26. Guo J-G, Guo C-C, He Z-Q, Cai X-Y, Mou Y-G. High MMP-26 expression in glioma is correlated
341 with poor clinical outcome of patients. *Oncology Letters*. 2018;16(2):2237-2242.
342 doi:10.3892/ol.2018.8880
- 343 27. Khamis ZI, Iczkowski KA, Man Y-G, Bou-Dargham MJ, Sang Q-XA. Evidence for a Proapoptotic
344 Role of Matrix Metalloproteinase-26 in Human Prostate Cancer Cells and Tissues. *J Cancer*.
345 2016;7(1):80-87. doi:10.7150/jca.13067
- 346 28. Savinov AY, Remacle AG, Golubkov VS, et al. Matrix metalloproteinase 26 proteolysis of the
347 NH2-terminal domain of the estrogen receptor beta correlates with the survival of breast cancer
348 patients. *Cancer Res*. 2006;66(5):2716-2724. doi:10.1158/0008-5472.CAN-05-3592

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365 **LIST OF TABLES**

366

367

368 **Table 1:** Characteristics of the study population according to histopathological group

Variables (n= 150)	Group								p-value
	Atrophy (n=25)		PIN (n=25)		BPH (n=50)		PA (n=50)		
	n	%	n	%	n	%	n	%	
Age group (years)									p ⁽¹⁾ = 0.447
41 a 59 (n=27)	3	12	5	20	12	24	7	14	
60 a 69 (n= 68)	12	48	11	44	17	34	28	56	
70+ (n=55)	10	40	9	36	21	42	15	30	
TOTAL	25	100	25	100	50	100	50	100	
Ethnicity/color									p ⁽²⁾ = 0.010*
White (n=15)	1	4.8	3	17.6	3	7.0	8	27.6	
Brown (n= 66)	9	42.9	9	52.9	30	69.8	18	62.1	
Black (n = 29)	11	52.4	5	29.4	10	23.3	03	10.3	
TOTAL	21	100	17	100	43	100	29	100	
alcohol Consumption									p ⁽¹⁾ = 0.286
Yes (n=44)	7	63.6	3	25.0	17	48.6	17	51.5	
No (n=47)	4	36.4	9	75.0	18	51.4	16	48.5	
TOTAL	11	100	12	100	35	100	33	100	
Smoking									p ⁽¹⁾ = 0.649
Yes (n=49)	9	60	6	42.9	19	50	15	41.7	
No (n=54)	6	40	8	57.1	19	50	21	58.3	
TOTAL	15	100	14	100	38	100	36	100	

369 (*). Significant difference at the level of 5.0%. (1) Using Pearson's Chi-square test. (2) Through Fisher's exact
 370 test. In this table, cases without information on each variable were not considered.

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388 **Table 2:** Results of PSA tests by groups, clinical and histopathological exam.

Variables Exams	Total (n= 150)		Atrophy (n= 25)		PIN (n= 25)		Quantity per group BPH (n= 50)		PA (n= 50)		p-Value
	n	%	n	%	n	%	n	%	N	%	
PSA											p ⁽¹⁾ = 0.002*
< 4	37	24.7	06	26.1	06	24	19	47.5	06	12.5	
4 to 10	72	48	16	69.6	14	56	16	40	26	54.2	
> 10	27	18	01	4.3	05	20	05	12.5	16	33.3	
Uninformed	14	9.3									
Clinical exam											
Presence of nodule	36	24									
Absence of nodule	71	47.3									
Uninformed	43	28.7									
Histopathological											
Atrophy	26	17.3									
NIP	10	6.7									
HPB	29	19.3									
ACP	40	26.7									
ASAP	02	1.3									
Others	08	5.3									
Uninformed	35	23.3									

389 (*) Significant difference at the level of 0.05 (1) Using Pearson's Chi-square test.

390

391 **Table 3:** Total PSA, free PSA, and free PSA/total PSA for each group.

Variables	Average \pm DP Median (P25; P75)					p Value
	Total (n=150)	Atrophy (n=25)	PIN (n=25)	BPH (n=50)	PA (n=50)	
Total PSA (n= 136)						
	10.68 \pm 15.37 5.98 (3.85; 9.13)	5.95 \pm 3.12 5.70 (3.90; 7.05)	8.22 \pm 8.66 5.62 (3.70; 9.62)	8.81 \pm 16.79 4.41 (2.13; 7.26)	15.80 \pm 18.90 7.93 (5.46; 18.34)	p ⁽¹⁾ = 0.001*
Free PSA (n= 102)						
	1.19 \pm 1.13 0.86 (0.50; 1.42)	1.05 \pm 0.37 0.88 (0.85; 1.43)	1.21 \pm 1.36 0.81 (0.40; 1.56)	1.11 \pm 1.09 0.82 (0.30; 1.37)	1.30 \pm 1.25 0.86 (0.51; 1.74)	p ⁽¹⁾ = 0.628
Free PSA/total PSA (n= 102)						
	17.56 \pm 10.29 16.33 (10.30; 23.57)	21.20 \pm 6.31 22.03 (16.30; 25.29)	19.29 \pm 14.64 14.93 (8.27; 28.64)	19.93 \pm 9.71 20.17 (15.25; 23.54)	12.85 \pm 7.53 11.02 (8.43; 17.00)	p ⁽¹⁾ = 0.001*

(*) Significant difference at the level of 0.05 (1). Kruskal Wallis test.

392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411

412 **Table 4 - Assessment of IHC intensity for MMP26**

Group	Negative		Weak		Moderate		Strong		Group Total		p-Value
	n	%	n	%	N	%	n	%	n	%	
	Atrophy	25	100	-	-	-	-	-	-	25	
PIN	3	12	22	88	-	-	-	-	25	100	
BPH	48	96	2	4	-	-	-	-	50	100	
PA	4	8	10	20	31	62	5	10	50	100	
TOTAL	80	53.3	34	22.7	31	20.7	5	3.3	150	100	

(*) Significant difference at 0.05. (1) Fisher's exact test.

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435 **Table 5:** Evaluation of PSA and clinical exams according to IHC

Variable	Immunohistochemistry						p-Value p	Intensity (IHC)						P-Value
	Total		Negative		Positive			Weak		Moderate		Strong		
	n	%	n	%	n	%		n	%	n	%	n	%	
Total PSA							$p^{(1)} = 0.002^*$							$p^{(2)} = 0.031^*$
< 4	37	27.2	27	38.6	10	15.2	5	15.6	5	17.2	-	-		
4 to 10	72	52.9	35	50	37	56.1	18	56.3	16	55.2	3	60		
> 10	27	19.9	8	11.4	19	28.8	9	28.1	8	27.6	2	40		
TOTAL	136	100	70	100	66	100	32	100	29	100	5	100		
Clinical examination							$p^{(1)} = 0.945$							$p^{(2)} = 0.905$
Present nodule	36	33.6	18	34	18	33.3	7	30.4	9	33.3	2	50		
without nodule	71	66.4	35	66	36	66.7	16	69.6	18	66.7	2	50		
TOTAL	107	100	53	100	54	100	23	100	27	100	4	100		

436 (*) Significant difference at the level of 5.0%. (1) Using Pearson's Chi-square test. (2) Through Fisher's
 437 exact test.

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458 **Table 6** – ROC analysis of groups regarding to the MMP-26 IHC

Groups	Cutt off (%)	AUC		Sensitivity (%)	Specificity (%)
		Value	CI 95%		
PA vs Atrophy/PIN/BPH)	≥ 15	0,94	0,90 a 0,98	92,0	80,0
PA/PIN vs Atrophy/BPH	≥ 10	0,97	0,94 a 0,99	92,0	97,3
PA vs Atrophy/BPH	≥ 10	0,97	0,95 a 1,00	94,0	97,3

459

460

461

462

463

464

465

466

467

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485 **LIST OF FIGURES**

486

487 **Figure 1.** Photomicrographs of the prostate (10 μ M). Histopathological analysis (HE) on
488 the left and immunohistochemistry (MMP-26) on the right. Absence of reactivity in the
489 atrophy (A and B) and hyperplasia (C and D) groups. Weak reactivity in most cases of
490 intraepithelial neoplasia (E and F) and moderate and intense immunoreactivity in the
491 adenocarcinoma group (G and H). Scale bar 10 μ m.

492

493

494

495

496

497

498

499

500

501

502

503

504

505

506

507

508

509

510

511


512

513


514

515

516




517 **Figure 2** – ROC curve for PA vs Atrofia+PIN+BHP regarding to the MMP-26
518 immunohistochemistry



519

520

521 Figure 3 – ROC curve for PA+ PIN vs Atrophy+HPB regarding to the MMP-26
522 immunohistochemistry.




523

524

525

526 Figure 4 – ROC curve for PA vs PIN+BHP regarding to the MMP-26
527 immunohistochemistry.

528



529

530

531

532

533

534

535

536

537

538

539

540

541

542

543

544

545

546

547

548

549

550

551

552

553

554

555

556

557

558

559

560

561